Back to News
Market Impact: 0.25
Retension Pharmaceuticals Prices $45 Million IPO At $12 Per Share
Source: Nasdaq
IPOs & SPACsHealthcare & BiotechCompany Fundamentals
Clinical-stage biopharmaceutical company Retension Pharmaceuticals priced an upsized IPO of 3.75 million shares at $12.00 per share. The article excerpt provides no further details on proceeds, use of funds, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- Wall Street Week | Michigan Manufacturing, AI Debt Investments, Baby Bonds, Canadian Coal Fight
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- SpaceX makes big move into wireless. These once 'obsolete' tech stocks could benefit
- MTY Food Group Inc Profit Retreats In Q3
- Why is T-Mobile stock tumbling today?
- Wall Street sees buying opportunity in banks as shares tank ahead of earnings
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- The $4.7 Trillion Bet: When Does AI Capex Become AI Revenue?
- Equity Research Automation Statistics: A 2026 Evidence Check